Compare Fubotv Inc (FUBO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Neurocrine Biosciences Inc — how do they compare? Fubotv Inc trades at $9.61 (market cap $1.06B), while Neurocrine Biosciences Inc trades at $158.66 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 15.5× Fubotv Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| FUBO | NBIX | |
|---|---|---|
Market Cap | $1.06B | $16.46B |
Sector | Technology | Health |
52-Week High | $54.72 | $185.50 |
52-Week Low | $8.09 | $123.10 |
Enterprise Value | $1.23B | $16.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.36, up 1.08% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growing to $1.62B in 2024 and projected net income turning positive at $123M for 2025. Recent CEO transition to former Disney executive Alisa Bowen and partnerships with major media companies signal strategic repositioning.
While valuation metrics appear attractive with P/E of 2.53 and P/S of 0.19, the stock faces execution risks in achieving profitability targets. Analyst consensus is mixed with 46.7% buy ratings and $15.33 price target, representing significant upside potential if the company can deliver on its EBITDA growth roadmap.
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
